EXAMINING THE GLYCEMIA RISK INDEX AND ITS ASSOCIATION WITH CONTINUOUS GLUCOSE MONITOR (CGM)-DERIVED GLYCEMIC RISK CATEGORIES IN PATIENTS WITH TYPE 1 DIABETES

被引：0
|
作者：
Litwin, J. [1 ]
Lockee, B. [1 ]
Vandervelden, C. [1 ]
Barnes, M. [1 ]
Mcdonough, R. [2 ]
Patton, S. [3 ]
Williams, D. [4 ]
Noland, K. [1 ]
Clements, M. [5 ]
机构：
[1] Childrens Mercy Hosp, Endocrinol, Kansas City, MO USA
[2] Childrens Mercy Kansas City, Endocrinol, Kansas City, MO USA
[3] Nemours Childrens Hlth, Ctr Healthcare Delivery Sci, Jacksonville, FL USA
[4] Childrens Mercy Hosp, Hlth Serv & Outcomes Res, Kansas City, MO USA
[5] Childrens Mercy Hosp, Endocrinol & Diabet, Kansas City, MO USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
728
引用
收藏
页码：A174 / A174
页数：1
相关论文
共 50 条
  • [41] Association between scanning frequency of flash glucose monitoring and continuous glucose monitoring-derived glycemic makers in children and adolescents with type 1 diabetes
    Suzuki, Junichi
    Urakami, Tatsuhiko
    Yoshida, Kei
    Kuwabara, Remi
    Mine, Yusuke
    Aoki, Masako
    Morioka, Ichiro
    PEDIATRICS INTERNATIONAL, 2021, 63 (02) : 154 - 159
  • [42] GLYCOMETRICS IN 70,167 PATIENTS WITH TYPE 2 DIABETES DERIVED FROM RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING (CGM)
    McMahon, C.
    Rodenzo, W.
    Agrawal, P.
    Welsh, J.
    Vigersky, R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A28 - A28
  • [43] Assessment of Glycemia Risk Index and Standard Continuous Glucose Monitoring Metrics in a Real-World Setting of Exercise in Adults With Type 1 Diabetes: A Post-Hoc Analysis of the Type 1 Diabetes and Exercise Initiative
    Morrison, Dale
    Vogrin, Sara
    Zaharieva, Dessi P.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2024,
  • [44] IMPACT OF CONTINUOUS GLUCOSE MONITORING ON GLYCEMIC CONTROL FOR PATIENTS WITH TYPE 2 DIABETES NOT ON INSULIN THERAPY WITH HIGH RISK FOR CARDIOVASCULAR DISEASE
    Reed, Joseph A.
    Dong, Tony
    Eaton, Elke
    Sullivan, Claire
    Rajagopalan, Sanjay
    Al-Kindi, Sadeer G.
    Neeland, Ian J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1884 - 1884
  • [45] Effect of Sitagliptin on 24-Hour Glycemic Variations in Japanese Patients with Type 2 Diabetes as Assessed by Continuous Glucose Monitoring (CGM)
    Taniguchi, Yukiko
    Mori, Yutaka
    Matsuura, Kenichi
    Itoh, Yohta
    Sezaki, Kazunori
    Yokoyama, Junichi
    Tajima, Naoko
    DIABETES, 2010, 59 : A558 - A558
  • [46] Discrepancies in glycemic metrics derived from different continuous glucose monitoring systems in adult patients with type 1 diabetes mellitus
    Zhou, Yongwen
    Mai, Xiaodong
    Deng, Hongrong
    Yang, Daizhi
    Zheng, Mao
    Huang, Bin
    Xu, Linlin
    Weng, Jianping
    Xu, Wen
    Yan, Jinhua
    JOURNAL OF DIABETES, 2022, 14 (07) : 476 - 484
  • [47] HYPOGLYCEMIA RISK IN CHILDREN AND YOUNG ADULTS WITH TYPE 1 DIABETES THROUGH INDICATORS OF GLYCEMIC VARIABILITY OBTAINED BY CONTINUOUS GLUCOSE MONITORING
    Hernandez Sandoval, G.
    Villalobos, J.
    Paz, J. J.
    Finol, M.
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 29 - 29
  • [48] EFFECTS OF MULTIPLE DAILY INJECTION THERAPY ON GLYCEMIC VARIABILITY IN A REAL FASTING IN TYPE 1 DIABETES EVALUATED BY CONTINUOUS GLUCOSE MONITORING (CGM)
    Nogueira, J.
    Villa, I.
    Burgos, M.
    Daghero, A.
    Proietti, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A217 - A217
  • [49] A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes
    Ágnes Benedict
    Emily R. Hankosky
    Kinga Marczell
    Jieling Chen
    David J. Klein
    J. Jaime Caro
    Jay P. Bae
    Brian D. Benneyworth
    PharmacoEconomics, 2022, 40 : 743 - 750
  • [50] A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes
    Benedict, Agnes
    Hankosky, Emily R.
    Marczell, Kinga
    Chen, Jieling
    Klein, David J.
    Caro, J. Jaime
    Bae, Jay P.
    Benneyworth, Brian D.
    PHARMACOECONOMICS, 2022, 40 (08) : 743 - 750
12345